SRR1430288
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.445
- MYOGENESIS+0.285
- PANCREAS_BETA_CELLS+0.221
- FATTY_ACID_METABOLISM+0.190
- SPERMATOGENESIS+0.168
- APICAL_SURFACE+0.157
- OXIDATIVE_PHOSPHORYLATION+0.156
- HEDGEHOG_SIGNALING+0.121
- ESTROGEN_RESPONSE_LATE+0.106
- CHOLESTEROL_HOMEOSTASIS+0.075
Top 10 suppressed
- IL6_JAK_STAT3_SIGNALING-0.542
- ALLOGRAFT_REJECTION-0.519
- INTERFERON_GAMMA_RESPONSE-0.500
- INTERFERON_ALPHA_RESPONSE-0.473
- E2F_TARGETS-0.398
- INFLAMMATORY_RESPONSE-0.384
- COMPLEMENT-0.382
- G2M_CHECKPOINT-0.379
- ANGIOGENESIS-0.336
- MYC_TARGETS_V1-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1434526 | GTEX | — | 0.930 |
| 2 | SRR1401424 | GTEX | — | 0.918 |
| 3 | SRR1440986 | GTEX | — | 0.913 |
| 4 | SRR821549 | GTEX | — | 0.912 |
| 5 | SRR1343481 | GTEX | — | 0.909 |
| 6 | SRR1444580 | GTEX | — | 0.909 |
| 7 | SRR1447693 | GTEX | — | 0.908 |
| 8 | SRR1357523 | GTEX | — | 0.906 |
| 9 | SRR1337564 | GTEX | — | 0.905 |
| 10 | SRR1310008 | GTEX | — | 0.904 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.445 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.285 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.221 | Cobimetinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.190 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.168 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.157 | Temsirolimus | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.156 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.121 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.106 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.075 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.068 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.033 | Inavolisib | — uncovered |